Mark S. Cragg

21.0k total citations · 1 hit paper
198 papers, 10.2k citations indexed

About

Mark S. Cragg is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Mark S. Cragg has authored 198 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Radiology, Nuclear Medicine and Imaging, 95 papers in Immunology and 77 papers in Molecular Biology. Recurrent topics in Mark S. Cragg's work include Monoclonal and Polyclonal Antibodies Research (97 papers), Chronic Lymphocytic Leukemia Research (46 papers) and T-cell and B-cell Immunology (44 papers). Mark S. Cragg is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (97 papers), Chronic Lymphocytic Leukemia Research (46 papers) and T-cell and B-cell Immunology (44 papers). Mark S. Cragg collaborates with scholars based in United Kingdom, United States and Latvia. Mark S. Cragg's co-authors include Martin J. Glennie, Jekaterina Ērenpreisa, Ruth R. French, Stephen A. Beers, H.T. Claude Chan, Andreas Strasser, Peter Johnson, Tim Illidge, Claire A. Walshe and Ronald P. Taylor and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark S. Cragg

191 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain

2017 504 citations Mark S. Cragg, Diego Gómez‐Nicola et al. Cell Reports profile →

Peers

Countries citing papers authored by Mark S. Cragg

Since Specialization

Citations

This map shows the geographic impact of Mark S. Cragg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Cragg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Cragg more than expected).

Fields of papers citing papers by Mark S. Cragg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Cragg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Cragg. The network helps show where Mark S. Cragg may publish in the future.

Co-authorship network of co-authors of Mark S. Cragg

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Cragg. A scholar is included among the top collaborators of Mark S. Cragg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Cragg. Mark S. Cragg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Portable RPA-CRISPR/Cas12a-Based Biosensing Platform for On-Site Detection of the Microcystin Synthetase E Gene in Lake Water 2025 ·ACS ES&T Engineering ·(unknown), Mark S. Cragg, Siwen Wang	0
2	P179 CD19hi B cells express T-bet and display activated metabolism and function in rheumatoid arthritis and systemic lupus erythematosus patient samples 2024 ·Lara D. Veeken ·(unknown), Maria Leandro, Mark S. Cragg, Florian Kollert, Franz Schuler, David Isenberg, Arne N. Akbar, Christian Klein, Venkat Reddy	1
3	XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression 2023 ·Leukemia ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Peter Johnson, Yosef Landesman, Mark S. Cragg, Francesco Forconi, Christopher J. Walker, Salim I. Khakoo, Matthew D. Blunt	12
4	Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy 2023 ·Nature Immunology ·Falk Nimmerjahn, Gestur Vidarsson, Mark S. Cragg	55
5	Development of C1q Affinity Chromatography for the Study of C1q–IgG Interactions 2023 ·The Journal of Immunology ·Michael J. Marshall, Alexander Knaupp, Christian Spick, (unknown), (unknown), Mark S. Cragg, Florian Cymer, Tilman Schlothauer	2
6	Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility 2022 ·Science Immunology ·Christian M. Orr, (unknown), Xiaojie Yu, H.T. Claude Chan, Yunyun Gao, Patrick J. Duriez, Steven G. Booth, (unknown), Tatyana Inzhelevskaya, (unknown), Christine A. Penfold, Armin Wagner, Martin J. Glennie, Ann L. White, Jonathan W. Essex, Arwen R. Pearson, Mark S. Cragg, Ivo Tews	30
7	FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms 2022 ·Cell Reports ·(unknown), Ali Roghanian, Robert Oldham, H.T. Claude Chan, Christine A. Penfold, Hyung J. Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Kerry L. Cox, Yury D. Bogdanov, Sonya James, Alison L. Tutt, (unknown), Peter T. Morley, Lekh N. Dahal, Ingrid Teige, Björn Frendéus, Stephen A. Beers, Mark S. Cragg	16
8	Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies 2021 ·Cancers ·Khiyam Hussain, Mark S. Cragg, Stephen A. Beers	9
9	Paradoxes of cancer: Survival at the brink 2020 ·Seminars in Cancer Biology ·Jekaterina Ērenpreisa, Kristīne Salmiņa, Olga V. Anatskaya, Mark S. Cragg	52
10	Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy 2017 ·Cancer Research ·Demin Li, (unknown), (unknown), (unknown), Kirstie L.S. Cleary, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nicola Ternette, Benedikt M. Kessler, Bart Cornelissen, Mark S. Cragg, Alison H. Banham	29
11	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy 2017 ·Cancer Research ·Lekh N. Dahal, Lang Dou, Khiyam Hussain, (unknown), (unknown), Kerry L. Cox, Salome Murinello, Ian Tracy, Francesco Forconi, Andrew J. Steele, Patrick J. Duriez, Diego Gómez‐Nicola, Jessica L. Teeling, Martin J. Glennie, Mark S. Cragg, Stephen A. Beers	59
12	Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures 2017 ·Molecular & Cellular Proteomics ·Harvey E. Johnston, Matthew Carter, Kerry L. Cox, (unknown), Antigoni Manousopoulou, Paul A. Townsend, Spiros D. Garbis, Mark S. Cragg	14
13	Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms 2017 ·The Journal of Immunology ·Kirstie L.S. Cleary, H.T. Claude Chan, (unknown), Martin J. Glennie, Mark S. Cragg	92
14	Lamin B1 regulates somatic mutations and progression of B-cell malignancies 2017 ·Leukemia ·Tetyana Klymenko, Johannes Bloehdorn, Jasmin Bahlo, Sandra Robrecht, (unknown), Kerry L. Cox, (unknown), Jun Wang, Jennifer Edelmann, Jonathan C. Strefford, Tomasz K. Wojdacz, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Mark S. Cragg, John G. Gribben, (unknown)	22
15	FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells 2016 ·The Journal of Immunology ·Samantha D. Pauls, (unknown), Sen Hou, Andrew Vaughan, Mark S. Cragg, Aaron J. Marshall	11
16	Fcγ receptors: genetic variation, function, and disease 2015 ·Immunological Reviews ·Chantal E. Hargreaves, Matthew Rose‐Zerilli, Lee R. Machado, Chisako Iriyama, Edward J. Hollox, Mark S. Cragg, Jonathan C. Strefford	69
17	Role of the pro-survival molecule Bfl-1 in melanoma 2014 ·The International Journal of Biochemistry & Cell Biology ·Charlotte K. Hind, Matthew Carter, Claire Harris, (unknown), (unknown), Mark S. Cragg	36
18	Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model 2013 ·Clinical Cancer Research ·Emily L. Williams, (unknown), Sonya James, Peter Johnson, Mark S. Cragg, Martin J. Glennie, Juliet C. Gray	34
19	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies 2011 ·Blood ·Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J. Cheadle, Sandeep Potluri, Sean H. Lim, Kazuyuki Shimada, H.T. Claude Chan, Andrew Tutt, Stephen A. Beers, Martin J. Glennie, Mark S. Cragg, Tim Illidge	222
20	Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection 2010 ·Blood ·Stephen A. Beers, Ruth R. French, H.T. Claude Chan, Sean H. Lim, (unknown), (unknown), (unknown), Sandra V. Dixon, Hyungjin Kim, Kerry L. Cox, Jonathan P. Kerr, David A. Johnston, Peter Johnson, J. Sjef Verbeek, Martin J. Glennie, Mark S. Cragg	241

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact